TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31629371

Group type: EXPERIMENTAL
Intervention: Abivertinib metabolites M7 and MII-6 quantification method using LC-MS/MS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stability assessments of M7 and MII-6
Number of subjects: 0
Study: 30582281

Group type: EXPERIMENTAL
Intervention: Low-dose prolonged-release tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose prolonged-release tacrolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose prolonged-release tacrolimus + ACEi/ARB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose prolonged-release tacrolimus + OAHT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACEi/ARB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study: 27906549

Group type: EXPERIMENTAL
Intervention: HFHC meal with 30 g of insoluble dietary fiber
Number of subjects: 10

Group type: COMPARATOR
Intervention: HFHC meal alone
Number of subjects: 10
Study: 25913272

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 with booster dose (R3R group)
Number of subjects: 15459

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 with comparator vaccine (R3C group)
Number of subjects: 15459

Group type: COMPARATOR
Intervention: Comparator vaccine (C3C group)
Number of subjects: 15459
Study: 23632396

Group type: EXPERIMENTAL
Intervention: FDT Matrix 30/2 examination with best refractive correction
Number of subjects: 48

Group type: COMPARATOR
Intervention: FDT Matrix 30/2 examination without refractive correction
Number of subjects: 48
Study: 21323490

Group type: EXPERIMENTAL
Intervention: Internet cognitive behaviour therapy (CBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Face-to-face cognitive behaviour therapy (CBT)
Number of subjects: 75
Study: 19776082

Group type: EXPERIMENTAL
Intervention: Electrocautery dissection and application of a collagen patch coated with human fibrinogen and thrombin (TachoSil)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment (ST) with stapling device
Number of subjects: 60
Study: 16924989

Group type: EXPERIMENTAL
Intervention: Helioseal pit/fissure sealant
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: DuraFinish surface sealant
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no sealant applied)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond MultiPurpose adhesive
Number of subjects: 96
Study: 14742372

Group type: EXPERIMENTAL
Intervention: EMLA cream after ultrasound pretreatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: EMLA cream application for 5 min
Number of subjects: 42

Group type: COMPARATOR
Intervention: EMLA cream application for 10 min
Number of subjects: 42

Group type: COMPARATOR
Intervention: EMLA cream application for 15 min
Number of subjects: 42

Group type: COMPARATOR
Intervention: EMLA cream application for 60 min without ultrasound pretreatment
Number of subjects: 42
Study: 11328297

Group type: EXPERIMENTAL
Intervention: epoetin alfa
Number of subjects: 145
Study: 9715644

Group type: COMPARATOR
Intervention: BiPAP-S/T
Number of subjects: 15

Group type: COMPARATOR
Intervention: VPAP-S/T
Number of subjects: 15
Study: 9148253

Group type: EXPERIMENTAL
Intervention: Timolol hydrogel (T-Gel 0.1%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aqueous timolol 0.5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2255026

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 6991107

Group type: EXPERIMENTAL
Intervention: DA plus cis‐dichlorodiammineplatinum(II) (DAP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dianhydrogalactitol plus Adriamycin (DA)
Number of subjects: 41
Study: 29394351

Group type: EXPERIMENTAL
Intervention: Life-Space Assessment for Persons with Cognitive Impairment (LSA-CI)
Number of subjects: 118
Study: 27161603

Group type: EXPERIMENTAL
Intervention: EDOF contact lenses
Number of subjects: 52
Study: 26411031

Group type: EXPERIMENTAL
Intervention: CQR-300, 300 mg daily
Number of subjects: 0
Study: 24680843

Group type: EXPERIMENTAL
Intervention: Double-layer locked/unlocked suture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single-layer locked suture
Number of subjects: 36
Study: 23152674

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study: 19729582

Group type: EXPERIMENTAL
Intervention: BtxA + mCIMT
Number of subjects: 32

Group type: COMPARATOR
Intervention: BtxA + conventional rehabilitation
Number of subjects: 32
Study: 18829797

Group type: EXPERIMENTAL
Intervention: Higher rates of infusion of intravenous fat emulsion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 16060411

Group type: COMPARATOR
Intervention: manidipine 20 mg o.d. for 4 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: delapril 30 mg b.i.d. for 4 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: fixed combination of manidipine 10 mg plus delapril 30 mg o.d. for 8 weeks
Number of subjects: 55
Study: 12403690

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Montelukast and Budesonide (combination)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10879210

Group type: EXPERIMENTAL
Intervention: Iowa Case Management (ICM)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Standard treatment services
Number of subjects: 483
Study: 8972324

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 16
Study: 1729855

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2312

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2312
Study: 6420825

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 32
Study: 31126327

Group type: EXPERIMENTAL
Intervention: Siblings (treatment with benznidazole)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Non-siblings (controls)
Number of subjects: 833
Study: 29469212

Group type: EXPERIMENTAL
Intervention: Performance-based financing or pay-for-performance (P4P) methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Earlier contracting/P4P models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative data from key informant interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contracting and P4P approaches
Number of subjects: 0
Study: 26370560

Group type: EXPERIMENTAL
Intervention: Standardized minimal acupuncture in LI4
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Individualized acupuncture (Sifeng, LI4, ST36)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 144
Study: 24940305

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (3 times/week for 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mild aerobic exercise training (3 times/week for 3 months)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison between moderate and mild aerobic exercise training
Number of subjects: 50
Study: 21492178

Group type: EXPERIMENTAL
Intervention: P-Capt-filtered RBCs
Number of subjects: 43
Study: 19139444

Group type: EXPERIMENTAL
Intervention: CDE reminder‐feedback and educational outreach intervention
Number of subjects: 1468
Study: 18693600

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15151516

Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX) 180 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast (ML) 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX) 180 mg + Montelukast (ML) 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 11557915

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 5 mg
Number of subjects: 13
Study: 8228340

Group type: EXPERIMENTAL
Intervention: High-titer vaccine (100-fold greater than standard titer)
Number of subjects: 1972

Group type: COMPARATOR
Intervention: Medium-titer vaccine (10-fold greater than standard titer)
Number of subjects: 1972
Study: 3803483

Group type: EXPERIMENTAL
Intervention: Judging tense of printed verbs (V)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Judging symmetry of spatial patterns (S)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Common ensemble for both tasks (V and S)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preparation interval prior to verbal and spatial tasks
Number of subjects: 40
Study: 28782306

Group type: EXPERIMENTAL
Intervention: Nutrition behaviour change communication (BCC)
Number of subjects: 2341

Group type: COMPARATOR
Intervention: Non-BCC groups
Number of subjects: 2341
Study: 27670866

Group type: EXPERIMENTAL
Intervention: Mindful Eating Intervention (MEI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study: 24060855

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass)
Number of subjects: 23
Study: 23682661

Group type: EXPERIMENTAL
Intervention: GSK2190915 30 mg QD
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 20181971

Group type: EXPERIMENTAL
Intervention: Integrated antiretroviral therapy during tuberculosis therapy (combined integrated-therapy groups)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Sequential antiretroviral therapy after completion of tuberculosis therapy (sequential-therapy group)
Number of subjects: 642
Study: 17997391

Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study: 16310911

Group type: EXPERIMENTAL
Intervention: Trans-tibial amputations group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 14575193

Group type: EXPERIMENTAL
Intervention: PPE-15 in a four-page survey instrument
Number of subjects: 1445

Group type: COMPARATOR
Intervention: PPE-15 in a 12-page survey instrument
Number of subjects: 1445
Study: 11078178

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 to 10 mg twice a day
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 to 20 mg twice a day
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 8712033

Group type: EXPERIMENTAL
Intervention: Neuroleptic medication (doses above 2000 mg chlorpromazine equivalents daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Unmedicated controls
Number of subjects: 111
Study: 1281062

Group type: EXPERIMENTAL
Intervention: Subcutaneous salmon calcitonin (100 U Calcitonin Sandoz) for 21 days plus physical treatment and early mobilization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 50
Study: 3709030

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg/day for 6 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketoconazole with methylprednisolone
Number of subjects: 6
Study: 28922338

Group type: EXPERIMENTAL
Intervention: Esmolol (0.7 mg/kg bolus over 1 min followed by infusion at 10 μg/kg/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline bolus)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.2 μg/kg/min infusion)
Number of subjects: 14
Study: 27523491

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 mL)
Number of subjects: 216

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 216
Study: 24013647

Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks (Q2W)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks (Q4W)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Combined CZP arms (200 mg Q2W and 400 mg Q4W)
Number of subjects: 325
Study: 23050829

Group type: EXPERIMENTAL
Intervention: 24-month moderate, home-based physical activity program (150 minutes per week) and a behavioral intervention package.
Number of subjects: 156
Study: 21905974

Group type: EXPERIMENTAL
Intervention: MR enterography (MRE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CT enterography (CTE)
Number of subjects: 50
Study: 19161605

Group type: EXPERIMENTAL
Intervention: Physical activity programme (24 sessions; 2 sessions a week, 60 minutes per session)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Physical activity programme
Number of subjects: 424
Study: 16733114

Group type: EXPERIMENTAL
Intervention: Covered 30F steel SEMS
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10F polyethylene (PE) stents
Number of subjects: 100
Study: 15116824

Group type: EXPERIMENTAL
Intervention: External fixation (Group B)
Number of subjects: 40
Study: 10779091

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9484000

Group type: EXPERIMENTAL
Intervention: Hemolytic ocular film (HOF)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 248
Study: 8222743

Group type: EXPERIMENTAL
Intervention: Semi-rigid bandage ('Scotchrap')
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard adhesive tape treatment
Number of subjects: 136
Study: 3518772

Group type: EXPERIMENTAL
Intervention: Fenclofenac at 600 mg day-1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenclofenac at 1200 mg day-1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenclofenac at 1800 mg day-1
Number of subjects: 18
Study: 30286820

Group type: EXPERIMENTAL
Intervention: Policosanol (20 mg/day)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Policosanol + Fenofibrate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 102
Study: 26626320

Group type: EXPERIMENTAL
Intervention: Rotigotine (optimal/maximum dose <16 mg/24h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24185607

Group type: EXPERIMENTAL
Intervention: Patient-controlled levobupivacaine 1.25 mg/ml via i.p. catheter as needed (maximum once per hour) with continuous saline infusion 10 ml/h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous infusion of levobupivacaine 1.25 mg/ml 10 ml/h and bolus saline as needed
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patient-controlled levobupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous infusion of levobupivacaine
Number of subjects: 40
Study: 22371462

Group type: EXPERIMENTAL
Intervention: Enrolled in SUPPORT trial
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Eligible but not enrolled infants
Number of subjects: 1316
Study: 20022262

Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17725600

Group type: EXPERIMENTAL
Intervention: Lansoprazole (proton pump inhibitor) for 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (6 normal subjects)
Number of subjects: 41
Study: 15851916

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) plus an optimized background regimen (OBR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) continued after HIV RNA level returns to pretreatment baseline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized background regimen (OBR) alone
Number of subjects: 0
Study: 12416946

Group type: EXPERIMENTAL
Intervention: Leflunomide added to existing methotrexate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to existing methotrexate therapy
Number of subjects: 0
Study: 10628925

Group type: EXPERIMENTAL
Intervention: Postal administration with financial incentive
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: Telephone administration with financial incentive
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: Clinic visit administration with financial incentive
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: Postal administration without financial incentive
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: Telephone administration without financial incentive
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: Clinic visit administration without financial incentive
Number of subjects: 1594
Study: 8845402

Group type: EXPERIMENTAL
Intervention: HSV vaccine
Number of subjects: 142

Group type: COMPARATOR
Intervention: Intermittent oral acyclovir (ACV)
Number of subjects: 142
Study: 1775083

Group type: EXPERIMENTAL
Intervention: Intranasal spray (4 doses of an oil‐based P solution at a concentration of 2 mg/0.1 ml, total dose approximately 11 mg of P)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ointment (quantity 0.1 ml, P concentration 20 mg/0.1 ml)
Number of subjects: 20
Study: 7068938

Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Diflunisal (all doses)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 201
Study: 29948276

Group type: EXPERIMENTAL
Intervention: SCPF + EMD
Number of subjects: 30

Group type: COMPARATOR
Intervention: SCPF
Number of subjects: 30
Study: 27822684

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX)
Number of subjects: 663

Group type: COMPARATOR
Intervention: S-1 plus cisplatin (CS)
Number of subjects: 663
Study: 25524950

Group type: EXPERIMENTAL
Intervention: Insulin glargine administered in the evening (2200 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin glargine administered in the morning (1000 h)
Number of subjects: 10
Study: 25022120

Group type: EXPERIMENTAL
Intervention: Rotating manipulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lifting-thrusting manipulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Corrective lenses
Number of subjects: 120
Study: 22249915

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standardized (attention control)
Number of subjects: 400
Study: 19300303

Group type: EXPERIMENTAL
Intervention: Stable isotope‐labelled nicotine infusion
Number of subjects: 139
Study: 16776576

Group type: EXPERIMENTAL
Intervention: phVEGF165 (vascular endothelial growth factor gene‐carrying plasmid)
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo (0.9% NaCl)
Number of subjects: 54
Study: 15478166

Group type: EXPERIMENTAL
Intervention: Verum sleeve (heat-retaining sleeve)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo sleeve (standard cotton/elastane sleeve)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Verum sleeve (heat-retaining sleeve) with correct belief
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Verum sleeve (heat-retaining sleeve) with incorrect belief
Number of subjects: 52
Study: 11771005

Group type: EXPERIMENTAL
Intervention: Bone-conducted stimuli at 40- and 50-dB
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conductive hearing loss
Number of subjects: 5
Study: 9341413

Group type: EXPERIMENTAL
Intervention: 5% glucose solution during the first 3 days of life in addition to being breastfed
Number of subjects: 180

Group type: COMPARATOR
Intervention: Exclusively breastfed nonglucose water group (NGW)
Number of subjects: 180
Study: 8428871

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5, 10, 15, and 20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 31
Study: 2889353

Group type: EXPERIMENTAL
Intervention: Radiotherapy (25 Gy over 5-7 days)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 694
Study: 29332677

Group type: EXPERIMENTAL
Intervention: Normal sleep (0000-0800 hours) and normal meal timing (1, 5, 11, and 12.5 hours after awakening)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Late sleep (0330-1130 hours) and late meal timing (4.5, 8.5, 14.5, and 16 hours after awakening)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal sleep and late meal timing
Number of subjects: 6

Group type: COMPARATOR
Intervention: Late sleep and normal meal timing
Number of subjects: 6

Group type: COMPARATOR
Intervention: Late sleep and late meal timing
Number of subjects: 6
Study: 29267415

Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioural Intervention (8 sessions applying CBT principles)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual services (Control group)
Number of subjects: 50
Study: 25790328

Group type: EXPERIMENTAL
Intervention: Resveratrol (150 mg per day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23993247

Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 73
Study: 21936938

Group type: EXPERIMENTAL
Intervention: High-energy protein supplement (HEPS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study: 19015627

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0
Study: 15164887

Group type: EXPERIMENTAL
Intervention: Caffeine (0.3 mg per kg per hour)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11393351

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 332

Group type: COMPARATOR
Intervention: Macrolides (azithromycin, clarithromycin, roxithromycin)
Number of subjects: 332